

Healthcare M&A

2021

Contributing editors
Jason Zemmel, Philippa Chatterton and Charlotte Beston



Publisher

Tom Barnes

tom.barnes@lbresearch.com

Subscriptions

Claire Bagnall

claire.bagnall@lbresearch.com

Senior business development manager

Adam Sargent

adam.sargent@gettingthedalthrough.com

Published by

Law Business Research Ltd

Meridian House, 34-35 Farringdon Street

London, EC4A 4HL, UK

The information provided in this publication is general and may not apply in a specific situation. Legal advice should always be sought before taking any legal action based on the information provided. This information is not intended to create, nor does receipt of it constitute, a lawyer-client relationship. The publishers and authors accept no responsibility for any acts or omissions contained herein. The information provided was verified between May and June 2021. Be advised that this is a developing area.

© Law Business Research Ltd 2021

No photocopying without a CLA licence.

First published 2019

Third edition

ISBN 978-1-83862-670-9

Printed and distributed by

Encompass Print Solutions

Tel: 0844 2480 112



Healthcare M&A

2021

Contributing editors

Jason Zemmel, Philippa Chatterton and Charlotte Beston

CMS Cameron McKenna Nabarro Olswang LLP

Lexology Getting The Deal Through is delighted to publish the third edition of *Healthcare M&A*, which is available in print and online at www.lexology.com/gtdt.

Lexology Getting The Deal Through provides international expert analysis in key areas of law, practice and regulation for corporate counsel, cross-border legal practitioners, and company directors and officers.

Throughout this edition, and following the unique Lexology Getting The Deal Through format, the same key questions are answered by leading practitioners in each of the jurisdictions featured.

Lexology Getting The Deal Through titles are published annually in print. Please ensure you are referring to the latest edition or to the online version at www.lexology.com/gtdt.

Every effort has been made to cover all matters of concern to readers. However, specific legal advice should always be sought from experienced local advisers.

Lexology Getting The Deal Through gratefully acknowledges the efforts of all the contributors to this volume, who were chosen for their recognised expertise. We also extend special thanks to the contributing editors, Jason Zemmel, Philippa Chatterton and Charlotte Beston of CMS Cameron McKenna Nabarro Olswang LLP, for their continued assistance with this volume.



London

June 2021

Reproduced with permission from Law Business Research Ltd

This article was first published in July 2021

For further information please contact editorial@gettingthedalthrough.com

Contents

| | |
|--|-----------|
| Introduction | 3 |
| Jason Zemmel, Philippa Chatterton and Charlotte Beston CMS Cameron McKenna Nabarro Olswang LLP | |
| Argentina | 4 |
| Bárbara V Ramperti and Martín J Mosteirin Marval O'Farrell Mairal | |
| Brazil | 11 |
| João Paulo Minetto, Carlos Orsolon, Roberto Casarini and Marcelo Peloso Demarest Advogados | |
| China | 15 |
| Cindy Hu East & Concord Partners | |
| Egypt | 22 |
| Michael Boutros and Moamen H Abdelmoamen Shahid Law Firm | |
| Germany | 28 |
| Christoph Lächler, Roland Wiring and Daniel Mahn CMS Germany | |
| Japan | 34 |
| Akiko Sueoka, Yo Uraoka and Yasutaka Tokuda Mori Hamada & Matsumoto | |
| Singapore | 41 |
| Erwan Barre and Yang Eu Jin RHTLaw Asia LLP | |
| Spain | 48 |
| Teresa Paz-Ares and Beatriz Cocina Uría Menéndez | |
| Switzerland | 55 |
| Andreas Rötheli, Stephan Erni, Sevan Antreasyan and Federico Trabaldo Togna Lenz & Staehelin | |
| United Kingdom | 62 |
| Jason Zemmel, Philippa Chatterton and Charlotte Beston CMS Cameron McKenna Nabarro Olswang LLP | |
| United States | 70 |
| Angela Humphreys Bass, Berry & Sims PLC | |
| Vietnam | 77 |
| Benjamin Yap Soon Tat and Le Thi Kim Quy RHTLaw Vietnam | |

Vietnam

Benjamin Yap Soon Tat and Le Thi Kim Quy

RHTLaw Vietnam

TRANSACTIONAL ISSUES

Structures

- 1 | What is the typical structure of a healthcare-related business combination in your jurisdiction?

Share purchase or capital purchase is typically selected for a healthcare-related business combination owing to its simplicity in procedure as compared to other structures, such as asset deals, mergers and consolidation. Asset deals are complicated by the fact that there are no clear guidelines for the purchase and sale of healthcare-related assets, whereas share deals enable the buyer to determine the level of investment in a more flexible and individualised way. Furthermore, a business combination carried out through a share deal ensures the investor can continue day-to-day business without significant changes. It is common for a target company to be structured as either a limited liability company or a joint stock company. Both are similar in terms of issues and procedures from a deal perspective.

Timeline

- 2 | How long do healthcare business combinations usually take, and what factors tend to be most significant in determining the timing to completion?

It will take between two and six months and in some cases up to a year for completion of a healthcare-related business combination. It is difficult to be more precise as it depends on the schedule of issuance or amendment of any required licences and certificates by the authority recording the investment, as well as on the process of rectifying the outstanding issues of the target company identified during the due diligence. Share deals are typically faster and carry fewer execution risks compared with asset deals, although, even in the case of share deals, these will take time given that there are still regulatory approvals and filings required (for example, acquisition approvals and licence amendments). Land-related issues can also significantly delay the process.

Representations and warranties

- 3 | What are the typical representations and warranties made by a seller in healthcare business combinations? What areas would be covered in more detail compared with a more general business combination?

Representations and warranties made by sellers in healthcare business combinations are not notably different from those in a business combination in other industries. In respect of healthcare entities that depend on the use of certain intellectual property rights or information technology, the seller must represent and warrant that it (or the target company in the case of a share deal) has all rights to use, develop, modify and maintain those intellectual property rights and information

technology. Moreover, lawful conduct of a healthcare business is closely supervised by the authorities and representations and warranties must cover regulatory compliance before closing.

As certain healthcare-related business areas are restricted to foreign investors (for example, foreign invested companies are not allowed to carry out distribution and retailing of pharmaceutical products activities), the seller should represent and warrant that the target company is not engaged in those areas. Furthermore, the conduct of healthcare-related businesses often requires numerous compulsory licences (treatment, clinic operation, treatment techniques, radiation, and X-ray...). Therefore, the representations during the investment process are more detailed on the compulsory licences and permits than for business combinations in most other industries.

Due diligence

- 4 | Describe the legal due diligence required in healthcare business combinations. What specialists are typically involved? What searches would typically be carried out?

The due diligence process carried out with regard to healthcare-related businesses differs from other due diligence processes as typical healthcare related checks are carried out. Those checks include an explicit check on the business lines of the healthcare target entity as there could be restrictions for foreign investors for certain business lines such as the pharmaceutical sector. For example, certain foreign invested clinics may have pharmacies within their premises. A careful due diligence must be carried out to ensure that both are not – or are not deemed to be – related.

Due diligence must also focus on the strict compliance of the target company with applicable regulation. In particular, it should emphasise the existence of valid treatment licences (ie, operation licence in respect of medical treatment entity) if the target company is a hospital since such licence is essential for the carrying out of hospital services.

Regarding due diligence on the major assets, these are commonly land use rights buildings and equipment (*inter alia*, healthcare-related equipment).

While carrying out the due diligence on employment law issues, it should be clarified whether all employees requiring any medical licence have been granted with the corresponding licence. Generally, only employees with direct patient contact are required by Vietnamese law to hold a medical licence. Foreign employees are also required to hold work permits.

Specific healthcare-related contracts are commonly medical and technical equipment rent-to-own lease agreements and other related activities and contracts regarding the set-up of pharmacies within the premises of the clinics. If there are pharmacies within the premises, then we would also need to ensure that strategic supply agreements are in place to ensure that strategic supply of pharmaceuticals will continue to be available post combination. There may also be related

real estate issues for pharmacies located within the premises of the clinics since foreign investors are not allowed to establish pharmacies. Issues relating to the sub-lease of premises for the pharmacy business will come into play and it must be clear that the clinic also has a real estate licence to sub-lease land. Such licences are typically difficult to obtain in conjunction with healthcare licences.

Concerning insurance, medical malpractice insurances are compulsory and therefore due diligence should also focus on that specific issue.

Risk exposure

- 5 | If due diligence is not correctly undertaken, what specific healthcare risks might buyers inherit?

A strong focus should be paid to contracts that could violate Vietnamese law as they could lead to a termination of licences with the consequence that the healthcare target entity can no longer operate its business. That applies in particular to contracts on pharmacy distribution businesses as foreign investors are not entitled to conduct this business. Furthermore, since 2018, criminal liability is now applicable to companies in Vietnam relating to specific healthcare-related crimes such as manufacturing or trading counterfeit medicines for treatment or prevention of diseases or polluting the environment. These crimes could lead to a temporary or permanent suspension of business activities or a monetary fine. Only in certain cases of investment will criminal liability not transfer (merger, consolidation). Apart from that, criminal responsibility remains. Thus, investors need to undertake comprehensive due diligence to avoid risking their acquired company losing the right to operate.

Furthermore, it should be ensured that the target company does fulfil all regulatory healthcare related obligations applicable for that facility when granted the operation licence since non-compliance with any related obligation could lead to a 24-month suspension from operation. In addition, in the case of a material breach of environment regulation, the healthcare entity may be subject to criminal liability. Depending on the breach, the healthcare entity may be subject to a fine up to 20 billion dong and may be permanently suspended from operation or banned from operation in some business lines or sectors for a period from one to three years.

Specific diligence issues

- 6 | How do buyers typically approach specific material diligence issues in healthcare business combinations?

The material diligence issues determined during the due diligence are usually agreed by the parties to be conditions subsequent. On certain material diligence issues the parties try to agree on indemnification provisions to reduce the investor's risks when this is possible.

Conditions before completion

- 7 | What types of pre-closing conditions are most common in healthcare business combinations?

Specific healthcare related pre-closing conditions mainly focus on the existence of all required licences and insurances since these licences and insurances are compulsory to conduct a healthcare related business. Customarily, the seller provides evidence that the medical malpractice insurance is valid, the medical malpractice insurance companies have been notified of a potential change of name of the target company, if any, and that the new or amended insurance policies have been issued by the insurance companies.

Pre-closing covenants

- 8 | What sector-specific covenants are usually included to cover the period between agreement and completion in healthcare business combinations?

There are no sector-specific covenants unique to healthcare business combinations. The seller is usually required to disclose business information relating to special healthcare-related factors including the number of patients, the pricing by practice and specialty amongst other things.

If the combination results in the change to the name of the target company, a covenant on the transfer, assignment or novation of rights and obligations on all signed contracts should be made to ensure the effectiveness of those contracts after the combination.

Change of control provisions in either insurance or finance documents are not usual but if they are present, they should be negotiated prior to closing.

W&I insurance

- 9 | What specific provisions are commonly seen in warranty and indemnity insurance policies for healthcare business combinations compared with general business combinations?

We do not commonly see W&I insurance in healthcare deals in Vietnam.

Specific documentation

- 10 | Is there any sector-specific documentation typically used in healthcare business combinations? Does this differ depending on the structure of the transaction?

To legally operate a healthcare related business, the company must have been granted specific permissions and licences especially with regard to specific medical equipment. Depending on the structure of the investment, the target company may be required to amend or renew these licences or permits. If the transaction is carried out as a share deal, there is generally no need for a specific documentation as there is no relevant change in the operating business of the target company itself. In this case, only notification to the Business Registration Office about the change of shareholders is required by law. In case of a transfer of assets or a merger of companies, transferring of legal titles might be necessary and could lead to a compulsory amendment or renewal of the relevant permits and licences, transfer of real estate ownership titles, transfer of intellectual property rights, etc.

Post-completion undertakings

- 11 | Which post-completion undertakings are common in healthcare business combinations? Which undertakings are common?

There is nothing specific or unique to healthcare business combinations. The usual post-completion undertakings that apply generally will be applicable here including licences where there is a change in the name of the target. Regarding healthcare-related businesses, special focus should be paid to medical treatment operation permits and licences as they are compulsory for conducting healthcare-related business. These post-completion undertakings are commonly agreed to be conditions subsequent to protect the investor from potential risks of failure.

REGULATION

Laws and regulations

12 What are some of the primary laws and regulations governing or implicated in healthcare-related business combinations? Are healthcare assets subject to specific regulation that would be material in a typical transaction? Is law and regulation of healthcare national or subnational?

These are:

- Law No.105/2016/QH13 of the National Assembly dated 6 April 2016 on Pharmacy, taking effect on 1 January 2017 (the Law on Pharmacy);
- Law No. 40/2009/QH12 of the National Assembly dated 23 November 2009 on Medical Examination and Treatment, taking effect as from 1 January 2011 (the Law on Medical Examination and Treatment);
- Law No. 23/2018/QH14 of the National Assembly dated 12 June 2018, taking effect on 1 July 2019 (the Law on Competition);
- Law No. 101/2015/QH13 of the National Assembly dated 27 November 2015, taking effect on 1 July 2016 (the Criminal Code);
- Decree No. 54/2017/ND-CP of the Government dated 8 May 2017 Guiding the Implementation of Law on Pharmacy, taking effect on 1 July 2017 (Decree 54);
- Decree No. 87/2011/ND-CP of the Government dated 27 September 2011 Detailing and Guiding the Implementation of Some Articles of the Law on Medical Examination and Treatment, taking effect on 15 November 2011 (Decree 87);
- Decree No. 109/2016/ND-CP of the Government dated 1 July 2016 Regulating on Issuance of Practicing Certificates to Healthcare Practitioners and Operation Licences to Healthcare Facilities, taking into effect on 1 July 2016 (Decree 109);
- Decree No. 155/2018/ND-CP of the Government dated 12 November 2018 Amending Some Articles of Decree 109, taking effect on 12 November 2018 (Decree 155);
- Decree No. 36/2016/ND-CP of the Government dated 15 May 2016 Regulating Medical Equipment Management, taking into effect as from 1 July 2016 (Decree 36), as amended by Decree No. 169/2018/ND-CP of the Government dated 31 December 2018 and Decree No. 03/2020/ND-CP dated 1 January 2020;
- Decree No. 102/2011/ND-CP of the Government dated 14 November 2011 Regarding Liability Insurance in Medical Examination And Treatment, taking effect on 1 January 2012 (Decree 102);
- Decree No. 35/2020/ND-CP dated 24 March 2020 Guiding the Law on Competition, taking effect on 15 March 2020 (Decree 35);
- Decree No. 117/2020/ND-CP of the Government dated 28 September 2020 Regulating Penalties for Administrative Violations Against Medical Law, taking effect on 15 November 2020 (Decree 117);
- Decision No. 866/QD-BYT of the Minister of Health dated 14 March 2017 Approving the Document 'The Standard of Leadership Abilities, Basic Management of the Director of A Hospital' (Decision 866); and
- Vietnam Standard TCVN 4470: 2012.

Medical machines and equipment shall be subject to classification regime, depending on possible levels of risks related to the design and production of such medical equipment. Depending on the group of the medical machines and equipment, the registration of publication of applicable standards (applicable to Group A) or the registration of free sale (applicable to Groups B, C and D) is required before any medical machine or equipment is to be sold on the Vietnamese market.

All laws and regulations are national.

Consents, notification and filings

13 What regulatory and third-party consents, notifications and filings are typically required for a healthcare business combination?

Depending on the way the investment into a healthcare-related business is carried out (share deal, asset deal, merger or amount of shares held by foreign investor for example), it may be necessary to amend or renew the permits and licences of the target company. Furthermore, it may be necessary to inform the relevant insurance or finance company about a possible change of control owing to the investment and request for an amendment or renewal of the insurance policies.

Similar to other more general businesses combinations, in case the acquirer is located in another jurisdiction, the acquisition of a healthcare business must be subject to approval of competent authority in charge of foreign investment, prior to acquisition.

Additionally, the new Law on Competition and its guiding Decree set out a notification obligation prior to making any combination, which applies to healthcare business as well as businesses in other industries. In particular, as from 15 May 2020, (the date on which the Decree guiding the Law on Competition comes into effect), any combination that falls within one of the following cases must be notified to the National Competition Committee prior to being carried out:

- total assets in the market of Vietnam of the enterprise proposing to participate in the combination or group of affiliated enterprises to which such enterprise is a member was 3 trillion dong or more in the financial year immediately preceding the year of proposed implementation of the combination;
- total sales turnover or input purchase turnover in the market of Vietnam of the enterprise or group of affiliated enterprises to which the enterprise is a member was 3 trillion dong or more in the financial year immediately preceding the year of proposed implementation of the combination;
- transaction value of the combination is 1 trillion dong or more; or
- combined market share of the enterprises proposing to participate in the combination was 20 per cent or more in the relevant market in the financial year immediately preceding the year of proposed implementation of such combination.

Ownership restrictions

14 Are there any restrictions on the types of entities or individuals that can wholly or partly own healthcare businesses in your jurisdiction?

Although it is not clearly expressed under the laws, individuals are not entitled to own healthcare businesses. To clarify, only enterprises that have been issued with registration licences (enterprise registration certificate, investment registration certificate, investment licences, as applicable) are allowed to apply for operation certificates for healthcare businesses.

In addition, there is a requirement on minimum capital applicable to foreign investors. In particular, the WTO's Commitment of Vietnam permits foreign investors to invest in healthcare businesses, provided that they are able to meet the minimum following capital amount:

- minimum total investment capital for a hospital is US\$20 million;
- minimum total investment capital for a polyclinic unit is US\$2 million; and
- minimum total investment capital for a specialty unit is US\$200,000.

The above requirements on capital, however, do not apply to investors coming from ASEAN countries (ie, being established in an ASEAN country) as per agreements under ASEAN Framework Agreement on Services.

In addition, foreign investors are not entitled to participate in or invest in the distribution and retail of pharmaceutical products and consequently foreign invested companies are not allowed to operate the same.

Directors

15 | Are there any restrictions on who can be director of healthcare businesses in your jurisdiction?

The concept of director of healthcare business does not exist under Vietnamese law (except for directors of hospitals). There is, however, under Vietnamese law a similar concept of 'person in charge of healthcare business', which may be used to describe the head of the healthcare business. In addition, the laws require that each healthcare business must appoint a person in charge of professional and technical operations. The requirements for qualifications (professional degrees and practising certificate) and experience (years of practising) vary depending on the position (whether being a hospital director, person in charge of healthcare business or person in charge of professional and technical operations) and types of healthcare business. For example, the person in charge of professional and technical operations must be a doctor with a practising certificate suitable for the scope of operation of the clinic and must have provided medical examination and treatment for at least 36 months after being granted the practising certificate, or has directly participated in providing medical examination and treatment for at least 54 months.

Operating outside the home jurisdiction

16 | What domestic regulatory issues might arise for a company based in your jurisdiction operating healthcare businesses in other jurisdictions?

The investment sector should be carefully taken into consideration. The Law on Investment does not allow investors to invest in the sectors of purchase or sale of humans, tissues or parts of the human body and activities relating to asexual reproduction. It means that Vietnamese investors are also not allowed to invest in those sectors in other jurisdictions.

Cross-border acquirers

17 | What domestic regulatory issues arise when the acquirers of healthcare businesses are based outside the jurisdiction?

The capital issue should be taken into consideration. Post-acquisition by a foreign investor, the target will become a foreign-owned business. The WTO's Commitment of Vietnam permits foreign investors to invest in healthcare businesses, provided that they are able to meet the minimum following capital amounts:

- minimum total investment capital for a hospital is US\$20 million;
- minimum total investment capital for a policlinic unit is US\$2 million; and
- minimum total investment capital for a specialty unit is US\$200,000.

The above requirements on capital, however, do not apply to investors coming from ASEAN countries as per agreements under the ASEAN Framework Agreement on Services.

Competition and merger control

18 | What specific competition or merger control issues may arise in healthcare business combinations?

There is no specific competition or merger control that may arise in healthcare business combinations only. Healthcare business combinations, as well as other more general business combinations, however,

are subject to the requirement on notification of combination if they fall within the cases where the notifications are required by law. In particular, as from 20 May 2020, any combination that falls within one of the following cases must be notified to the National Competition Committee prior to proceeding with such combination:

- total assets in the market of Vietnam of the enterprise proposing to participate in the combination or group of affiliated enterprises to which such enterprise is a member was 3 trillion dong or more in the financial year immediately preceding the year of proposed implementation of the combination;
- total sales turnover or input purchase turnover in the market of Vietnam of the enterprise proposing to participate in the combination or group of affiliated enterprises to which such enterprise is a member was 3 trillion dong or more in the financial year immediately preceding the year of proposed implementation of the combination;
- transaction value of the combination is 1 trillion dong or more; or
- combined market share of the enterprises proposing to participate in the combination was 20 per cent or more in the relevant market in the financial year immediately preceding the year of proposed implementation of such combination.

State and private healthcare combinations

19 | Are there any differences for healthcare business combinations if the transaction relates solely to businesses servicing private clients rather than state-funded clients?

No, there are not.

FINANCING AND VALUATION

Financing

20 | How do buyers typically finance healthcare-related business combinations?

Financing should be secured overseas. Lending in Vietnam is generally not allowed to finance any business combination.

Security

21 | Describe the typical security structures in healthcare business combinations, including confirmation of any registration or notary fees in respect of the security documents.

Local loans to finance an acquisition are not allowed in Vietnam.

Financial assistance

22 | Are there any financial assistance rules that arise in healthcare business combinations?

No further rules are relevant beyond the restriction of using local loans to finance an acquisition.

Price and consideration

23 | What pricing and consideration structures are typical in healthcare business combinations?

There is no typical pricing structure applicable to healthcare business combinations. Pricing structures vary according to how negotiations take place and whether the buyer is a financial buyer, whether there are market comparables, whether there was a valuation made in a previous round of financing, historical financial data, projected financial growth, and the experience and expertise of the management team. It

often comprises cash and non-cash (including contingent) consideration and can include earn-outs and clawbacks as part of the contingent consideration.

Enterprise value

24 | How are healthcare-related businesses typically valued?

Concerning the valuation on healthcare-related businesses, a specific focus should be laid on assets and factors that are healthcare specific and constitute the major value of the target company. Those specific factors are, *inter alia*, specific healthcare-related equipment as well as the licence for its use. Furthermore, the workforce of the healthcare related business is considered as a major asset as those businesses are particularly reliant on their workforce. Other important factors include the treatment plan as well as the quality of the services indicated by several factors such as percentage of procedures with complications, patient ratings and hospital acquired infection rate. Another relevant factor is the revenue per bed day and the bed per square foot. As is the case in numerous industries, investors usually value their target on the basis of financial metrics such as net assets, profits and EBITDA, which are stated in the latest financial report.

TAX

Typical issues in combinations

25 | What are some of the typical tax issues in healthcare business combinations and to what extent do these typically drive structuring considerations? Are there certain considerations that stem from the tax status of a target?

The healthcare sector in Vietnam is subject to several tax incentives (such as import duties, CIT tax, VAT).

If the target company is entitled to a preferential CIT rate of 10 per cent, as it qualifies as an investment in social activities (which is assessed based on criteria of scale, staff, land, construction, medical equipment and instruments, etc), the combination could lead to a loss of this privilege as it might provoke a change in any of the applicable criteria. The tax authorities will then assess whether the target company still qualifies as an investment in social activities enjoying those incentives or not. In particular, a target company will be considered investing in social activities if it satisfies prescribed criteria, as follows.

- Regarding the scale: general hospitals must have at least 31 beds and specialised hospital must have at least 21 beds. In respect of hospitals located in Ha Noi City, Ho Chi Minh City, Hai Phong City and Da Nang City, these numbers are 100 beds in case of general hospitals and 500 beds in case of specialised hospitals.
- Regarding the staff: having to comply with Decree No. 109/2016/ND-CP of the government dated 1 July 2016 Regulating Issuance of Practicing Certificates to Healthcare Practitioners and Operation Licences to Healthcare Facilities, as amended by Decree No. 155/2018/ND-CP of the government dated 12 November 2018. For example, with regard to general hospitals, the number of full-time healthcare practitioners in each department must account for at least 50 per cent of the total number of healthcare practitioners in such department.
- Regarding the land: having to comply with National Standard on Design of General Hospital TCVN 4470:2012. For example, a general hospital having over 500 beds must have minimum area of 40,000 square metres.

It should then be considered whether the combinations will exclude the target company from enjoying tax incentives.

Tax risks for healthcare businesses

26 | What are the typical tax risks that are associated with healthcare businesses? What measures are normally taken to mitigate those typical tax risks in healthcare business combinations?

Tax risks are likely to happen when the combination leads to a change of scale and structure of the target company as a consequence of which the target company would not be entitled to tax incentives anymore. This might happen in respect of CIT incentives. A tax due-diligence should be properly carried out to ensure whether the target company is entitled to any tax incentive. A representation and warranty should also be made to ensure that the combination will not result in a change to the scale and structure of the target company that may result in the exclusion from the tax incentives.

PUBLIC RELATIONS AND GOVERNMENT POLICY

Public relations

27 | How do the parties address the wider public relations issues in healthcare business combinations?

With regard to public relation issues of an investment in a healthcare related business, the parties try to focus on the positive effects of a healthcare business combination. As Vietnam is in need of healthcare-related investments, positive effects are very well suited to be pointed out. Thus, the parties try to highlight that investments are done in order to improve the living standard on healthcare-related issues and add value to Vietnamese society. Investments with negative effect on public health are avoided. The investors try to point out that the patients' interests are at the centre of each investment decision. Investments in Vietnamese healthcare-related businesses are supposed to grant local people access to healthcare in remote areas and to improve the quality of healthcare. By improving human lives, it will strengthen Vietnam's most important asset: human resources.

Policy

28 | How do parties address the wider political issues in healthcare business combinations?

The Vietnamese government tries to transform its economy into a market economy as well as to address the needs of the Vietnamese middle class and its rising standard of living. Thus, policies have been encouraging (foreign) investors to engage in the healthcare sector. In order to do so, Vietnamese laws and regulations on healthcare related businesses are currently mostly investor-friendly. Nevertheless, parties usually agree that if there are changes to laws and regulations prior to completion of transaction that may cause a material adverse effect, the transaction will not be carried out.

UPDATE AND TRENDS

Recent developments

29 | What are the current trends, and what developments are expected in healthcare business combinations in your jurisdiction in the coming year?

Vietnam is one of 17 countries that are classified by BMI Research to the group of countries where the pharmacy market shows a rapid development (with the market scale of pharmacy of Vietnam is expected to reach US\$7.7 billion by 2021, and US\$16.1 billion by 2026). As per Fitch's forecast, Vietnam's healthcare market will reach US\$23 billion in 2022 at a compound annual growth rate (CAGR) of 10.7 per cent. Especially,

in the context of the covid-19 pandemic, the concern for the health of Vietnamese people has increased the burden on the public health system. The government is therefore offering numerous opportunities for private enterprises engaged in the medical and pharmaceutical sectors. In recent years, the healthcare business has become very attractive for private investors and the Vietnam market has attracted a new wave of M&A activity from both offshore and onshore investors. Together with new regulations passed by the government (one of which is the 2020 Law on Investment, which provides that the health sector is one of five key investment sectors subject to incentives on tax, land rental and credit support), foreign investors are taking advantage of M&A activities by approaching the Vietnamese market without needing to spend too much time requesting the issuance of investment licences and constructions of production lines.

Vietnam's recent trend in smart healthcare includes disease prevention, medical examinations and treatment, and health management. The Ministry of Health, through issuance of Decision No. 4888/QD-BYT dated 18 October 2019 Introducing Scheme for Application and Development of Smart Healthcare Information Technology from 2019 to 2025, set out a roadmap to digitise patient records at hospitals and establish smart business healthcare (ie, implementing the artificial intelligence (AI) applications in medical examination and treatment establishments). This is the beginning of an ambitious multidisciplinary journey that will benefit from access to the global industry's best practices.

Another remarkable point in the pharmaceuticals sector that should be highlighted is the coming into effect of the European Union Vietnam Free Trade Agreement (EVFTA) and United Kingdom Vietnam Free Trade Agreement (UKFTA) on 1 August 2020 and 1 January 2021 respectively. Accordingly, EU and UK pharmaceutical companies will be allowed to establish foreign-invested enterprises in Vietnam, which will be permitted to:

- import and sell pharmaceuticals which they have legally imported to distributors or wholesalers who have the right to distribute pharmaceuticals in Vietnam;
- build their own warehouses to store pharmaceuticals which they have legally imported into Vietnam;
- provide information on pharmaceuticals which they have legally imported into Vietnam to healthcare professionals or its successor and Vietnam's other competent authorities; and
- carry out clinical studies and testing to ensure that such pharmaceuticals that they have legally imported into Vietnam are suitable for domestic consumption.

Vietnam has also committed to apply a zero per cent import tax on around 71 per cent of pharmaceutical products imported from the EU and UK. This promises to create a positive wave in the pharmaceutical businesses in Vietnam.

Additionally, Vietnam also committed under EVFTA and similarly under the UKFTA to open for the EU bidders to participate in bidding packages for 34 public hospitals in Vietnam.

With the incentives and encouragement provided to investors from EU and UK, M&A activity in the healthcare sector in general and pharmaceutical sector in particular is therefore forecast to be active in the coming years.

RHTLaw Vietnam

Benjamin Yap Soon Tat

benjamin.yap@rhtlaw.com.vn

Le Thi Kim Quy

quy.le@rhtlaw.com.vn

Unit 1101, Sofitel Central Plaza
17 Le Duan Boulevard, Ben Nghe Ward
District 1, Ho Chi Minh City
Vietnam
Tel: +84 28 3820 6448
www.rhtlaw.com.vn

Coronavirus

- 30 | What emergency legislation, relief programmes and other initiatives specific to your practice area has your state implemented to address the pandemic? Have any existing government programmes, laws or regulations been amended to address these concerns? What best practices are advisable for clients?

In response to the covid-19 pandemic, the Vietnamese government has applied various measures to prevent and minimise the spread of the disease. This includes border closures and entry bans; quarantine and lockdown; closure of non-essential businesses, schools and workplaces; and suspension of transportation. The duration, level and scale of such measures have been adjusted over time to correspond with the progression of the pandemic.

The government also facilitated a robust healthcare system by way of issuing several decisions requiring rapid production of medical equipment and suspending exports of anti-covid-19 drugs to ensure health system capacities during the complicated development of the pandemic.

Preferential economic policies and relief measures have been implemented in various sectors to prevent the adverse socio-economic impact on businesses, society and individuals caused by the pandemic. For example:

- issuance of a list of medical supplies being exempted from tax until the pandemic ended including face masks, hand sanitisers, protective suits;
- exemption or deferment of tax and land rental in some cases for individuals and enterprises affected by the pandemic; and
- permittance of suspension of or delay in performance of some labour-related obligations such as obligations of contribution to retirement and survivorship funds and trade union fee due to the pandemic.

So far, the government has mainly issued new policies, programmes, laws or regulations to address the concerns about the pandemic rather than amending the existing ones.

With regard to the M&A process in Vietnam, since several preferential policies and relief measures have been issued and implemented during this unpredictable time, it is advisable that investors should carefully and comprehensively carry out due diligence to identify whether the target company has properly applied those policies, especially

focusing on tax and labour issues. Any oversight in the due diligence process can be a potential costly mistake, which could lead to unnecessary losses and damages to the business.

The force majeure event should also be paid attention to when entering into any transactional documents during the M&A process. For avoidance of potential dispute, at the first stage and in transactional documents, the parties should clearly cater for covid-19 like pandemics, which would be considered as a force majeure event.

Other titles available in this series

| | | | |
|-------------------------------|-----------------------------------|--------------------------------|------------------------------|
| Acquisition Finance | Distribution & Agency | Investment Treaty Arbitration | Public M&A |
| Advertising & Marketing | Domains & Domain Names | Islamic Finance & Markets | Public Procurement |
| Agribusiness | Dominance | Joint Ventures | Public-Private Partnerships |
| Air Transport | Drone Regulation | Labour & Employment | Rail Transport |
| Anti-Corruption Regulation | e-Commerce | Legal Privilege & Professional | Real Estate |
| Anti-Money Laundering | Electricity Regulation | Secrecy | Real Estate M&A |
| Appeals | Energy Disputes | Licensing | Renewable Energy |
| Arbitration | Enforcement of Foreign | Life Sciences | Restructuring & Insolvency |
| Art Law | Judgments | Litigation Funding | Right of Publicity |
| Asset Recovery | Environment & Climate | Loans & Secured Financing | Risk & Compliance Management |
| Automotive | Regulation | Luxury & Fashion | Securities Finance |
| Aviation Finance & Leasing | Equity Derivatives | M&A Litigation | Securities Litigation |
| Aviation Liability | Executive Compensation & | Mediation | Shareholder Activism & |
| Banking Regulation | Employee Benefits | Merger Control | Engagement |
| Business & Human Rights | Financial Services Compliance | Mining | Ship Finance |
| Cartel Regulation | Financial Services Litigation | Oil Regulation | Shipbuilding |
| Class Actions | Fintech | Partnerships | Shipping |
| Cloud Computing | Foreign Investment Review | Patents | Sovereign Immunity |
| Commercial Contracts | Franchise | Pensions & Retirement Plans | Sports Law |
| Competition Compliance | Fund Management | Pharma & Medical Device | State Aid |
| Complex Commercial Litigation | Gaming | Regulation | Structured Finance & |
| Construction | Gas Regulation | Pharmaceutical Antitrust | Securitisation |
| Copyright | Government Investigations | Ports & Terminals | Tax Controversy |
| Corporate Governance | Government Relations | Private Antitrust Litigation | Tax on Inbound Investment |
| Corporate Immigration | Healthcare Enforcement & | Private Banking & Wealth | Technology M&A |
| Corporate Reorganisations | Litigation | Management | Telecoms & Media |
| Cybersecurity | Healthcare M&A | Private Client | Trade & Customs |
| Data Protection & Privacy | High-Yield Debt | Private Equity | Trademarks |
| Debt Capital Markets | Initial Public Offerings | Private M&A | Transfer Pricing |
| Defence & Security | Insurance & Reinsurance | Product Liability | Vertical Agreements |
| Procurement | Insurance Litigation | Product Recall | |
| Dispute Resolution | Intellectual Property & Antitrust | Project Finance | |

Also available digitally

lexology.com/gtdt